Telefonische Erreichbarkeit

Aufgrund eines erhöhten Anrufaufkommens können längere Wartezeiten entstehen. Wenn Sie uns nicht erreichen, versuchen Sie es bitte später erneut oder hinterlassen Sie eine Rückrufbitte per E-Mail oder Live-Chat.

Kontakt

Parasitic infections

BA0028-0581-GRQ

  • M/F
  • 18 - 55 years old
  • Healthy

Clinical trial of a new compound that is being developed for the treatment of parasitic infections

  • From Januar 2027
  • 9 to 16 days
  • 0 to 5 visits

€3.833,- bis €6.569,-

Unverbindlich anmelden

A special experience in which I was well supported. 

Jesse Deelnemer ICON

Find out if you qualify for this trial

  • You are a healthy male or female
  • You are between 18 and 55 years old
  • You weigh more than 50 kg
  • Your Body Mass Index (BMI) is between 18 and 29.9 kg/m2

Good to know about this trial

  • Het onderzoeksmiddel is eerder onderzocht bij bij gezonde personen
  • Dit onderzoek bestaat uit twee delen. Je kunt maar aan één deel deelnemen.
  • Dit is een onderzoek met een radioactief (14C) gemerkt middel

 

BMI berechnen

Geben Sie Ihre Größe und Ihr Gewicht ein. Anschließend sehen Sie, ob Ihr BMI die Anforderungen dieser Studie erfüllt.

A special experience in which I was well supported. 

Jesse Deelnemer ICON

Wie funktioniert es

Wie funktioniert es?

Weiter lesen

Study groups

Register without obligation for the group of your preference

The research physician about the research

Additional information

The study compound may potentially be used to treat parasitic infections in humans. It has been safely used for many years to treat parasitic worm infections in animals. Researchers are now studying the study compound to see if it can also help treat certain human parasitic infections.

This trial consists of two parts. You can only participate in one part.

In Part 1, you will first be given the radioactively labeled study compound once as a small drink. This will be slowly administered into your cheek pouch using a syringe without a needle. After this, you will drink some water.
In Part 2, you will first be given the study compound as a tablet by mouth with water. This is followed by a solution containing the radioactively labeled study compound given directly into a blood vessel.

In this trial we will investigate how quickly and to what extent the study compound is absorbed, transported, and eliminated from the body. To investigate this, the compound contains a small amount of a radioactive substance. The radioactivity disappears from the body at the same time as the compound through the feces, urine and/or breath. The compound has a radiation exposure lower than the natural background radiation that you are exposed to in the Netherlands in 1 month. This background radiation comes from space, soil, air, water, food and construction materials. To measure radioactivity levels in your body, blood, urine and feces (the last two only apply in Part 1) will be collected during the trial.

Who can participate?

Target group

  • You are a healthy male or female.
  • You are at least 18 and at most 55 years old.
  • Your weight is at least 50 kg and your Body Mass Index (BMI) is at least 18.0 and at most 29.9 kg/m2. 
  • Both non-smokers and light smokers or occasional smokers (max 5 cigarettes per day) are allowed to participate in this clinical trial. You are not allowed to smoke during your stay in our research facility.
  • As a female you can only participate if you are not breastfeeding and if you meet one of the following conditions:
    • You have passed the menopause (no periods for at least 12 months);
    • You have been sterilized.
  • As a male you can only participate if you meet one of the following conditions:
    • You use a condom in combination with an additional contraception method used by your female partner until 6 months after the last dose;
    • You have been sterilized or your female partner is sterilized or has passed menopause (no periods for at least 12 months);
    • You are only sexually active with a same-sex partner;
    • You are not sexually active according to your lifestyle.

Note:

  • You cannot participate in the trial if you have participated in another clinical trial in the 3 months prior to the admission to this clinical trial (counting from the last dose in the previous trial) .
  • You can only participate in this trial if you have not participated in another trial with a radioactive (14C) labeled compound in the past 12 months. This timeframe is longer for clinical trials involving higher doses of radioactivity. Please contact us to see if this applies to you.
  • To determine if you are suitable to participate in this trial, you will undergo a medical screening. Depending on availability, this can be performed in Groningen or in Utrecht.

What is the compensation for this research?

Compensation

You will receive a gross compensation of € 4.569,- for full participation in Part 1. If you have to return for the 24-hour visits, you will receive a gross compensation of € 278 per visit.

For participation in Part 2 of the trial, you will receive a gross compensation of € 3.833,-.

Travel expenses will be reimbursed based on the distance traveled (€ 0.23 per kilometer) with a minimum of € 14.23 and a maximum of € 193.20 (840 kilometers) per round trip, regardless of the mode of transportation.

How long does this research take?

Period of stay and research

Part 1 of the trial consists of 1 period during which you will stay in the research facility in Groningen for 16 days (15 nights). Depending on the radioactivity levels in your body at the end of the stay, you may have to return to the research facility for a maximum of six 24-hour visits. The follow-up visit will be on the last day of your stay at the research facility.
Part 2 of the trial consists of 1 period during which you will stay in the research facility in Groningen for 9 days (8 nights), followed by five consecutive short visits. The last short visit will be the follow-up visit.

Note: You must be available for all dates to be able to participate in this clinical trial. The location in Groningen is Van Swietenlaan 6.

Further information about this research

Additional information

The compound has already been tested in humans. In these clinical trials, the following side-effects were observed most often: blurred vision, headache, and dizziness. All side effects were only temporary. You may also experience other, yet unknown, side effects. Prior to the medical screening, you will receive written information about the trial, which also describes the possible side effects. This information will also be discussed with you at the start of the medical screening. You can then ask the screening physician or nurse any questions you may have. Once everything is clear to you, you can decide whether to give written consent to participate in the trial. The medical screening will only take place after you have given written consent to participate in the trial. We want to emphasize that even after giving written consent, participation in any clinical trial is voluntary. You can decide at any time not to participate or to stop the medical screening or the trial. You do not need to provide a reason for why you no longer wish to participate.

Prior to screening you have to stay fasted for 4 hours. You can only drink water prior to your visit. This means that we will ask you to fast prior to any participation in the trial. You have not yet signed the form for participation in the trial. After the screening it will become clear whether you can participate.

Current trials

Meedoen aan een ander onderzoek?

View all clinical trials